Advancing Precision Medicine in PDAC: An Ethical Scoping Review and Call to Action for IHC Implementation DOI Open Access

Lyanne A. Delgado-Coka,

Lucia Roa‐Peña, Andrew Flescher

и другие.

Cancers, Год журнала: 2025, Номер 17(12), С. 1899 - 1899

Опубликована: Июнь 6, 2025

Pancreatic ductal adenocarcinoma (PDAC) presents significant challenges in diagnosis, prevention, and treatment. Predictive biomarkers offer the potential to revolutionize clinical management, particularly preoperative setting, but their implementation requires careful consideration of ethical implications. This scoping review analyzes landscape using immunohistochemistry (IHC) for molecular subtyping PDAC, focusing on its utility, accessibility, impact patient care. We conducted a systematic literature search PubMed, Scopus Google Scholar databases (2015–2025) COVIDENCE, which identified 130 references. Of these, 79 were reviewed full-text format, 9 ultimately met inclusion criteria our analysis. IHC offers several advantages as companion diagnostic tool. It is relatively inexpensive, widely available most pathology laboratories, can be readily integrated into existing workflows. contrasts with more complex methods, such gene expression profiling, costly, require specialized equipment expertise, may not accessible all settings. Furthermore, accurate analysis localized targeting individual cells; therefore, digesting sample bulk would less informative than spatial localization techniques IHC. Because biomarker regulation occur at level transcription or translation, protein-level assessment via often mRNA Standardized protocols are therefore essential translating PDAC clinically actionable treatment strategies, especially aggressive subtypes like basal-like tumors. deployable IHC-based approach optimize therapy selection, maximizing benefits minimizing exposure ineffective potentially toxic treatments. critically dimensions this method, grounded principles autonomy, beneficence, non-maleficence, justice. The urges medical community fully utilize IHC-driven improve outcomes while ensuring equitable responsible access precision oncology patients.

Язык: Английский

Immunosuppressive tumor microenvironment in pancreatic cancer: mechanisms and therapeutic targets DOI Creative Commons

Da Pan,

Xinyue Li,

Xiao Qiao

и другие.

Frontiers in Immunology, Год журнала: 2025, Номер 16

Опубликована: Май 15, 2025

Pancreatic cancer is projected to become the second leading cause of cancer-related death by 2030. Conventional interventions including surgery, radiotherapy, and chemotherapy provide only modest survival benefits, underscoring an urgent need for more effective therapies. Although immunotherapy has revolutionized management several solid tumors, its clinical benefit in pancreatic so far been disappointing. Mounting evidence indicates that a highly immunosuppressive tumor microenvironment (TME), dominated tumor-associated macrophages (TAMs), myeloid-derived suppressor cells (MDSCs), regulatory T (Tregs), drives immune evasion, progression, metastasis, chemoresistance through complex cytokine chemokine networks. This review summarizes current knowledge these mechanisms provides emerging strategies aimed at re-educating or depleting cellular constituents enhance efficacy cancer.

Язык: Английский

Процитировано

0
Advancing Precision Medicine in PDAC: An Ethical Scoping Review and Call to Action for IHC Implementation DOI Open Access

Lyanne A. Delgado-Coka,

Lucia Roa‐Peña, Andrew Flescher

и другие.

Cancers, Год журнала: 2025, Номер 17(12), С. 1899 - 1899

Опубликована: Июнь 6, 2025

Pancreatic ductal adenocarcinoma (PDAC) presents significant challenges in diagnosis, prevention, and treatment. Predictive biomarkers offer the potential to revolutionize clinical management, particularly preoperative setting, but their implementation requires careful consideration of ethical implications. This scoping review analyzes landscape using immunohistochemistry (IHC) for molecular subtyping PDAC, focusing on its utility, accessibility, impact patient care. We conducted a systematic literature search PubMed, Scopus Google Scholar databases (2015–2025) COVIDENCE, which identified 130 references. Of these, 79 were reviewed full-text format, 9 ultimately met inclusion criteria our analysis. IHC offers several advantages as companion diagnostic tool. It is relatively inexpensive, widely available most pathology laboratories, can be readily integrated into existing workflows. contrasts with more complex methods, such gene expression profiling, costly, require specialized equipment expertise, may not accessible all settings. Furthermore, accurate analysis localized targeting individual cells; therefore, digesting sample bulk would less informative than spatial localization techniques IHC. Because biomarker regulation occur at level transcription or translation, protein-level assessment via often mRNA Standardized protocols are therefore essential translating PDAC clinically actionable treatment strategies, especially aggressive subtypes like basal-like tumors. deployable IHC-based approach optimize therapy selection, maximizing benefits minimizing exposure ineffective potentially toxic treatments. critically dimensions this method, grounded principles autonomy, beneficence, non-maleficence, justice. The urges medical community fully utilize IHC-driven improve outcomes while ensuring equitable responsible access precision oncology patients.

Язык: Английский

Процитировано

0